PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION

A pharmaceutical composition comprising A) one or more ASO or a pharmaceutically acceptable salt thereof; B) one or more permeation enhancer; C) one or more optional pharmaceutically acceptable excipient; and D) one or more optional coating. Said composition for use in the treatment, prevention, or...

Full description

Saved in:
Bibliographic Details
Main Authors GENNEMARK, PETER, TIVESTEN, ANNA, CLEMMENSEN, NICLAS, WALTER, KATRIN, PUTRA, OKKY, MATIC, HANNA, ELEBRING, MARIE, UPADHYAY, PRATIK PANKAJ, RADEVIK, ANDREAS, TILLMAN, LLOYD, DELLAMARY, LUIS, DAVIES, NIGEL, MARUCCI, MARIAGRAZIA
Format Patent
LanguageEnglish
French
Published 24.03.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A pharmaceutical composition comprising A) one or more ASO or a pharmaceutically acceptable salt thereof; B) one or more permeation enhancer; C) one or more optional pharmaceutically acceptable excipient; and D) one or more optional coating. Said composition for use in the treatment, prevention, or amelioration of a disease associated with PCSK9 or PNPLA3 in a subject. La présente invention concerne des compositions pharmaceutiques comprenant A) un ou plusieurs oligonucléotides antisens (ASO) ou un sel pharmaceutiquement acceptable de ceux-ci; B) un ou plusieurs promoteurs de perméation; C) un ou plusieurs excipients pharmaceutiquement acceptables; et D) un ou plusieurs enrobages éventuels. Ladite composition est destinée à être utilisée dans le traitement, la prévention ou le soulagement d'une maladie associée à PCSK9 ou PNPLA3 chez un sujet.
Bibliography:Application Number: CA20213191517